Major Series B to Bridge Phase 3 and Commercialization

Swiss clinical-stage biotech Vaderis Therapeutics AG has raised $152 million in a Series B financing round. The funds, which include participation from Goldman Sachs Alternatives, will be used to support the global Phase 3 HEROIC trial and regulatory preparations for engasertib, a potential treatment for hereditary hemorrhagic telangiectasia (HHT). This financing is structured as equity and does not include upfront payments, milestones, or royalties. By securing capital to advance a single, rare disease asset from Phase 3 through commercialization, the company has simultaneously reduced clinical risk and the potential for future dilution.

Mechanism of Action and Phase 2 Data for Engasertib

Engasertib (VAD044), an investigational oral allosteric AKT1/AKT2 selective inhibitor, is currently in Phase 3 development. In HHT, it aims to address the vascular endothelial signaling imbalance and AKT overactivation caused by ACVRL1 and ENG gene mutations, thereby reducing abnormal blood vessel formation and bleeding. In a Phase 2 trial (NCT05406362), the 40mg dose of engasertib demonstrated a 41.4% reduction in the duration of nosebleeds compared to 23.8% in the placebo group, and a 27.8% reduction in the frequency of nosebleeds compared to 18.0% in the placebo group. The most common target-related adverse events in the 40mg group were mild-to-moderate rash (42%) and reversible hyperglycemia (12%). Balancing efficacy and safety for chronic administration will be a key consideration in the design of the HEROIC trial.

HHT Market with No Approved Therapies

HHT affects approximately 1 in 3,800 individuals and can cause recurrent nosebleeds, iron deficiency anemia, and arteriovenous malformations in the lungs, brain, and liver. Currently, there are no drugs approved by the FDA, EMA, or PMDA specifically for the treatment of HHT, and engasertib is also not yet approved in any country. Current treatments include iron supplementation, blood transfusions, and laser or embolization procedures for nosebleeds, as well as off-label use of Avastin (bevacizumab, a VEGF-A inhibitor) and Votrient (pazopanib, a VEGFR tyrosine kinase inhibitor) from Roche. Market research estimates the HHT market at $215 million to $710 million in 2025, with one forecast projecting $2.43 billion by 2035, supporting the potential for a first-in-class therapy to command a premium price.

Leading Position and Competitive Landscape

The HEROIC trial is a global Phase 3 study expected to begin in 2026. If successful, engasertib would be positioned to be the first targeted therapy approved for HHT. A key competitor is Diagonal Therapeutics' ALK1 clustering antibody, DIAG723, which has initiated a Phase 1/2 trial (DIAMOND) in July 2026. Terana Biosciences' AKT1 inhibitor, TER-1754, is also in Phase 1a/1b development. While other potential therapies, such as a low-dose pazopanib Phase 2 trial and Boehringer Ingelheim's Ofev (nintedanib, a VEGFR/FGFR/PDGFR inhibitor) Phase 2 trial (EPISTOP), are in development, Vaderis' early lead could stimulate partnership or acquisition interest. Long-term value will depend on the success of the Phase 3 trial, the safety profile for chronic administration, and the achievement of FDA and EMA approvals.